BioMérieux-Pierre Fabre

Group BIOMERIEUX PIERRE FABRE:
- Pierre Fabre Médicament: French 2nd largest independent pharmaceutical laboratory, Pierre Fabre Médicament has orientated its development on specific therapeutic axes. Investment in R&D enabled the developement of new molecules ; this financial effort will reinforce the company's global expansion. 290 million euros, 20 % of turnover channelled into Research.
- bioMérieux: 2 fields of application In vitro clinical diagnostics Industrial microbiological testing. Established in more than 130 countries.
- Pierre Fabre Dermo-Cosmétique
- Pierre Fabre Santé: Pierre Fabre Santé and Inava Odonto Stomatologie distribute preventative and general public health medicines, while concentrating its efforts on specific therapeutic axes
Centre d’immunologie (www.cipf.com): Discovery, development and production of biotechnological products to prevent and treat severe immune-mediated human diseases.
- Dolisos Laboratoires

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Bio
- Cosmoceuticals
- Curative
- Diagnostics
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Phyto
- Prescription drugs (Rx)
- Preventive
- Proteins
- Technology

Therapeutic targets:

- Cancer
- Cardiovascular
- Dermatology
- Infectious Diseases
- Mental Health
- Reproductive Health
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: France

b. Continent(s) active: Europe , North America

c. Countries active:

Corporate data:

Number of Employees: 11700

Turnover:

Amount:	Year:	Currency:
2,06 Milliards	2000	Euro

Year founded: 1961